Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 36, Issue 3, 1997, Pages 143-151

  Inoue, Ikuo ^a   Takahashi, Keiichi ^a   Noji, Satoru ^a   Awata, Takuya ^a   Negishi, Kiyohiko ^a   Katayama, Shigehiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Acarbose; Impaired glucose tolerance; Non insulin dependent diabetes mellitus; Proinsulin

Indexed keywords

ACARBOSE; C PEPTIDE; CHOLESTEROL; GLICLAZIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PROINSULIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE;

ACARBOSE; AGED; BLOOD GLUCOSE; C-PEPTIDE; CHOLESTEROL; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FASTING; GLICLAZIDE; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; POSTPRANDIAL PERIOD; PROINSULIN; TIME FACTORS; TOLBUTAMIDE; TRIGLYCERIDES; TRISACCHARIDES;

EID: 0030749393     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(97)00045-4     Document Type: Article

References (23)

1. S.P. Clissold, C. Edwards, Acarbose, a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential, Drugs 35 (1988) 214-243.
2. G.M. Reaven, Role of insulin resistance in human disease, Diabetes 37 (1988) 1595-1607.
3. N.M. Kaplan, The deadly quartet, upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension, Arch. Intern. Med. 149 (1989) 1514-1520.
4. E. Ferrannini, S.M. Haffner, B.D. Mitchell, M.P. Stern, Hyperinsulinaemia: The key feature of a cardiovascular and metabolic syndrome, Diabetologia 34 (1991) 416-422.
5. P. Gorden, C.M. Hendricks, J. Roth, Circulating proinsulin-like component in man: Increased proportion in hyperproinsulinemic state, Diabetologia 10 (1974) 469-474.
6. G.M. Reaven, Y.-D.I. Chen, C.B. Hollenbeck, W.H.H. Sheu, D. Ostrega, K.S. Polonsky, Plasma insulin, C-peptide and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance, J. Clin. Endocrinol. Metab. 76 (1993) 44-48.
7. W.K. Ward, E.C. Lacava, T.L. Paquette, J.C. Bead, B.J. Wallum, D.J. Porte, Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus in experimental insulin resistance, Diabetologia 30 (1987) 698-702.
8. N. Yoshioka, T. Kuzuya, A. Matsuda, M. Taniguchi, Y. Iwamoto, Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-depedent) diabetes mellitus, Diabetologia 31 (1988) 355-360.
9. J.H. Fuller, M.J. Shipley, G. Rose, R.J. Jarrett, H. Keen, Coronary heart disease risk and impaired glucose tolerance: the Whitehall study, Lancet i (1980) 1373-1376.
10. R.J. Jarrett, P. McCartney, H. Keen, The Bedford survey: The year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycemic control and risk indices for coronary heart disease in borderline diabetics, Diabetologia 22 (1982) 79-84.
11. D.K. Nagi, T.J. Hendra, A.J. Ryle, et al., The relationships of concentrations of insulin, intact proinsulin and 32,33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects, Diabetologia 33 (1990) 532-537.
12. N. Yoshida, T. Kuzuya, A. Matsuda, Y. Iwamoto, Effect of dietary treatment on serum insulin and proinsulin response in newly diagnosed NIDDM, Diabetes 38 (1994) 262-266.
13. K.S. Polonsky, B. Gumbiner, D. Ostrega, K. Griver, H. Tager, R.R. Henry, Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss NIDDM, Diabetes 43 (1994) 871-877.
14. World Health Organization Expert Committee. Second Report on Diabetes Mellitus. Tech. Rep. Ser. No. 646. WHO, Geneva, 1980.
15. Y. Watanabe, H. Horie, K. Hata, T. Ono, S. Tomono, S. Kawazu, A new radioimmunoassay of human proinsulin, Peptide Hormones Pancreas (in Japanese) 13 (1993) 69-73.
16. I. Inoue, K. Takahashi, S. Katayama, et al., A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance, Diabetic Med. 13 (1996) 330-336.
17. M. Shimizu, S. Kawazu, S. Tomono, et al., Age-related alteration of pancreatic β-cell function, Diabetic Care 19 (1996) 8-11.
18. J.L. Chiasson, The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance, Diabetic Med. 13 (1995) S23-S24.
19. I. Inoue, K. Takahashi, S. Katayama, et al., Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity and β-oxidation in fructose-fed rats, Metabolism 44 (1995) 1626-1630.
20. R.F. Coniff, J.A. Shapiro, T.B. Scaton, G.A. Bray, Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus, Am. J. Med. 98 (1995) 443-451.
21. C.J. Rhodes, C. Alarcon, What β-cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism, Diabetes 43 (1994) 511-517.
22. Y.-P. Zhou, V. Grill, Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle, J. Clin. Invest. 93 (1994) 870-876.
23. G. Nijpels, C. Popp-Snijders, P.J. Kostense, L.M. Bouter, R.J. Heine, Fasting proinsulin and 2 h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: The Study, Dibetologia 39 (1996) 113-118.